The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA phase III trial, which were published in The ...

(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...

One of the primary challenges in the regulatory affairs of the pharmaceutical industry is keeping pace with the ever-evolving regulatory landscape.

EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...

The European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...